300
Why use fosfomycin?
-Current guidelines published by the Infectious Diseases Society of America and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) recommend fosfomycin, nitrofurantoin, and trimethoprim-sulfamethoxazole (TMP-SMX) as first-line agents to treat acute uncomplicated UTIs in adult females, reserving fluoroquinolones, amoxicillin-clavulanate, and other β-lactams as second-line agents.
-Elevated rates of resistance (>10–20%) to TMP-SMX, as well as fluoroquinolones, are now widely reported for uropathogenic isolates of E. coli in Canada and elsewhere.
-The most recently published Canadian study, describing antimicrobial resistance rates among E. coli isolated from patients with urinary tract infections, reported on isolates collected from 2010 to 2013 and found susceptibility rates of 74.7% to TMP-SMX, 77.4% to ciprofloxacin, 81.3% to amoxicillin-clavulanate, 96.1% to nitrofurantoin, and 99.4% to fosfomycin.